Stopping GLP-1 drugs can quickly erase cardiovascular benefits Even brief interruption tied to change in risk of heart attack, stroke and death Sara Moser and Alaska Adams / WashU Medicine Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S
Ozempic The chart shows that Novo Nordisk has two patents covering the compound for semaglutide, namely, the 343 patent and the 122 patent
The result: a medication built on the same active pharmaceutical ingredient - semaglutide - but operating in a completely different regulatory category
Asilsoy, S., Bekem, O., Karaman, O., Uzuner, N., and Kavukcu, S
While this effect contributes to weight loss and glycemic control by prolonging satiety and moderating glucose excursions, it can also produce gastrointestinal symptoms and affect perioperative care
Gupta R, Debbaneh M, Butler D, Huynh M, Levin E, Leon A,